CSIMarket
 
Aquestive Therapeutics Inc   (AQST)
Other Ticker:  
 
 
Price: $4.2400 $0.57 15.531%
Day's High: $4.39 Week Perf: 48.77 %
Day's Low: $ 3.69 30 Day Perf: 77.41 %
Volume (M): 3,705 52 Wk High: $ 4.39
Volume (M$): $ 15,708 52 Wk Avg: $1.84
Open: $3.71 52 Wk Low: $0.72



 Market Capitalization (Millions $) 274
 Shares Outstanding (Millions) 65
 Employees -
 Revenues (TTM) (Millions $) 48
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 1

Aquestive Therapeutics Inc
Aquestive Therapeutics Inc. is a pharmaceutical company that focuses on developing and commercializing innovative products to address unmet medical needs. The company specializes in oral drug delivery solutions, offering proprietary technology platforms that enable the development of orally administered therapeutics for a wide range of diseases and conditions. Aquestive Therapeutics aims to improve the treatment experience for patients by providing alternatives to injections or infusions. The company's portfolio includes products for central nervous system and neurology disorders, as well as treatments for rare diseases. Aquestive Therapeutics is dedicated to advancing drug delivery technology and transforming the way medications are administered.


   Company Address: 30 Technology Drive Warren 7059 NJ
   Company Phone Number: 941-1900   Stock Exchange / Ticker: NASDAQ AQST
   AQST is expected to report next financial results on March 05, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Aquestive Therapeutics Showcases Promising Pharmacokinetic and Pharmacodynamic Data for Anaphylm at AAAAI Annual Meeting.

Published Thu, Feb 15 2024 1:01 PM UTC

Aquestive Therapeutics Presents Positive Pharmacokinetic and Pharmacodynamic Data for Anaphylm at AAAAI Annual MeetingWarren, N.J., (Date) - Aquestive Therapeutics, a leading pharmaceutical company dedicated to advancing medicines that significantly improve patients' lives through innovative science and delivery technologies, has announced the presentation of compelling phar...

Clinical Study

Aquestive Therapeutics Commences Phase 3 Clinical Study for Groundbreaking Oral Epinephrine Film: Anaphylm

Published Tue, Dec 5 2023 1:01 PM UTC



Aquestive Therapeutics, a leading pharmaceutical company focused on using innovative science and delivery technologies to revolutionize patient care, has recently made a significant breakthrough in the field of epinephrine administration. On December 5, 2023, the company announced the dosing of the first patient in its Phase 3 pivotal clinical study for Anaphylm (e...

Aquestive Therapeutics Inc

Pharma Giant's Remarkable Top-line Progress Unveiled as Financial Period Ends

Article: Aquestive Therapeutics Inc Reports Positive Financial Results for Fiscal Year 2023
Aquestive Therapeutics Inc, a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, recently announced its financial results for the fiscal year ending September 30, 2023. The company showed significant improvement in certain key areas compared to the previous year and also outperformed its industry peers.
One of the most notable highlights of the financial results was the decrease in the loss per share, which improved from $-0.23 per share in the prior year to $-0.03 per share in the current year. This demonstrates a positive trend for the company, indicating progress towards profitability. Moreover, the earnings per share also improved from $-0.10 per share in the preceding reporting period.

Aquestive Therapeutics Inc

Lackluster earnings at AQST amid the second quarter of 2023 earnings season

Aquestive Therapeutics Inc, a biopharmaceutical company specializing in developing and commercializing innovative products for the treatment of various diseases, recently reported its second-quarter earnings for 2023. The results showed a significant improvement compared to the same period last year, with the company reducing its losses per share.
During the second quarter of 2023 earnings season, AQST reported a loss of $-0.10 per share, a substantial improvement from the loss of $-0.36 per share in the same reporting season a year ago. Additionally, the earnings per share fell compared to the preceding reporting season, where AQST reported a positive EPS of $0.11 per share.

Aquestive Therapeutics Inc

A sharpe Contraction -9.258 %, in revenue at AQST over the first quarter of 2023

Investors in Aquestive Therapeutics Inc may be concerned by the company's cumulative net loss of $-33 million during the 12 months leading up to the first quarter of 2023. This resulted in a negative return on investment (ROI) of -164.78%. Furthermore, within the Healthcare sector, there were 911 other companies that had a higher return on investment, indicating that Aquestive Therapeutics Inc is not performing as well as some of its competitors.
However, there are some positive signs for the company. The most recent fiscal period was profitable, with EPS of $0.11 per share compared to a deficit of $-0.32 in the previous year. Although revenue decreased by -9.258% to $11.13 million, this was an improvement on the previous quarter where the company had a revenue of $10.68 million and a bottom line of $-0.18 per share. Aquestive Therapeutics Inc recorded net profits of $8.068 million in the fiscal first quarter of 2023, a significant improvement on a net deficit of $-13.220 million in the same period a year ago.






 

Aquestive Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com